Mogrify

Mogrify company information, Employees & Contact Information

Explore related pages

Related company profiles:

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems, 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type. Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease. Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications. Based in Cambridge, UK, the Company has raised over $40 million USD funding from Parkwalk, Ahren Innovation Capital, 24Haymarket, Trend Investment Group, Dr. Darrin M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management.
Looking for a particular Mogrify employee's phone or email?

Mogrify Questions

News

Mogrify Extends Series A Financing to $46 Million USD - Business Wire

Mogrify Extends Series A Financing to $46 Million USD Business Wire

Mogrify to accelerate novel IP and cell therapies using $3.7m USD funding - News-Medical

Mogrify to accelerate novel IP and cell therapies using $3.7m USD funding News-Medical

Mogrify appoints Dr Jonathan Appleby as Chief Scientific Officer - Cambridge Network

Mogrify appoints Dr Jonathan Appleby as Chief Scientific Officer Cambridge Network

Mogrify secures £830k grant funding from SBRI Healthcare - UK Tech Investment News

Mogrify secures £830k grant funding from SBRI Healthcare UK Tech Investment News

February: mogrify cell therapy | News and features - University of Bristol

February: mogrify cell therapy | News and features University of Bristol

Julian Gough - mrc-lmb.cam.ac.uk

Julian Gough mrc-lmb.cam.ac.uk

Darrin Disley returns to lead Mogrify’s new cell revolution - Cambridge Independent

Darrin Disley returns to lead Mogrify’s new cell revolution Cambridge Independent

Top newly founded UK university spinouts you should know about in 2021 - UKTN

Top newly founded UK university spinouts you should know about in 2021 UKTN

Cambridge startup OutSee Ltd aims to unearth new drug targets with its AI genomics tech - Business Weekly

Cambridge startup OutSee Ltd aims to unearth new drug targets with its AI genomics tech Business Weekly

CEO resigns amid disposals at listed MedTech - BusinessCloud

CEO resigns amid disposals at listed MedTech BusinessCloud

Mogrify secures £12.72 million Series A investment led by Ahren Innovation Capital - UK Tech Investment News

Mogrify secures £12.72 million Series A investment led by Ahren Innovation Capital UK Tech Investment News

Series A Extension adds $10m to bring Mogrify total of $46m - Cambridge Independent

Series A Extension adds $10m to bring Mogrify total of $46m Cambridge Independent

Top Mogrify Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant